| 摘要 |
This invention relates to a novel class of partial or full muscarinic receptor agonists, intermediates for their preparation, and pharmaceutical compositions for the treatment or prevention of diseases, the treatment or prevention of which is mediated by muscarinic receptor agonism. They are compounds of the invention of formula I (see fig.I) wherein, preferably, X is NR4R5 and R4 and R5 are taken together with the nitrogen atom to which they are attached to form an optionally substituted (five to nine)-membered saturated heterocyclic ring selected from piperidine, pyrrolidine, thiomorpholine, hexametheneimine, morpholine, thiazolidine and 1,2-tetrahydrooxazine; Y is N or CH; Z is pyridyl or phenyl optionally substituted with from one to three substituents independently selected from the group consisting of (C1-C6)alkyl, halo, hydroxy, (C1-C6)alkoxy, amino, (C1-C6)alkylamino, di(C1-C6)alkylamino and trifluoromethoxy; R2 is phenyl optionally substituted with halo, hydroxy, fluoro or methoxy; and R3 is phenyl optionally substituted with from one to three substituents independently selected from the group consisting of (C1-C6)alkyl, halo, hydroxy, (C1-C6)alkoxy, amino,
|
